Literature DB >> 2911043

Improved radiolabeled monoclonal antibody uptake by lavage of intraperitoneal carcinomatosis in mice.

R L Wahl1, M Liebert.   

Abstract

The effect of peritoneal lavage with saline on tumor and systemic uptake of intraperitoneally administered tumor-specific (131I-5G6.4) and nonspecific (125I-UPC-10) radiolabeled monoclonal antibodies was evaluated in a nude mouse model of human intraperitoneal ovarian carcinomatosis (IP3 model). Peritoneal lavage at 2 or 6 hr postintraperitoneal antibody injection significantly improves intraperitoneal tumor/nontumor uptake ratios of specific antibody apparently by limiting systemic exposure to antibody. This enhancement tends to be more dramatic if lavage is performed within 2 hr, rather than 6 hr, of intraperitoneal antibody administration, though both times result in significant improvements in target/background ratios over no lavage. Twenty-four-hour tumor/nontumor ratios for specific antibody 5G6.4 generally are 1.5-fourfold higher following lavage than those achieved in control animals, without decreasing absolute tumor uptake of specific radiolabeled antibody. By contrast, nonspecific antibody UPC-10 binding is lower in tumor and normal tissues following lavage, with no lavage-induced improvement in tumor/nontumor ratios seen. Peritoneal lavage is a simple method to allow for specific antibody binding to accessible intraperitoneal tumors yet to limit systemic exposure thus increasing the therapeutic margin. This method may have considerable applicability in the enhancement of intraperitoneal immunoconjugate delivery to intraperitoneal tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2911043

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  3 in total

1.  Investigations into the route of uptake and pharmacokinetics of intraperitoneally-administered monoclonal antibodies: I. Transdiaphragmatic blockade of the terminal lymphatics in the rat.

Authors:  J S Barrett; R L Wahl; J G Wagner; R Brown; S J Fisher
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 2.  Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.

Authors:  R M Reilly; J Sandhu; T M Alvarez-Diez; S Gallinger; J Kirsh; H Stern
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

3.  Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; J Plomley; I H Shon; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1993 Jan-Jun
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.